Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $373.0052W HIGH $677.90
Volume
55.64 K
Value Traded
140.13 M
Short % Float
7.45%
-0.33%Week
+3.9%1 Month
+8.64%3 Month
+23.77%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
17.08 B
EPS (TTM)
17.61
P/E Ratio
34.86
Ent. Value
16.56 B
Total Shares
27.92 M
Float Shares
22.62 M
Insiders
18.95%
Institutions
89.60%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MEDP Catalyst Timeline
Dated clinical, regulatory and corporate events for Medpace Holdings, Inc. Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for Medpace Holdings, Inc. Common Stock
85Total events
1Upcoming
0Tier-1 (high impact)
2016 to 2026Coverage
Event history 50
●Quarterly UpdateCorporate
2022 revenue guidance $1.44B-$1.46B, 2023 revenue guidance $1.68B-$1.74B
Past FDA Catalysts and PDUFA Decisions
How MEDP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B66 / 100
Pipeline Score
$10.7B
Pipeline Value
Fair Value
Valuation Signal
16
Drugs Scored
2.1x
rNPV / MCap
Top 5%
Mid Cap(rank 34 of 658)
Percentile Rank
Medpace Holdings, Inc. Common Stock holds a solid B-grade pipeline (66/100), with $12.5B risk-adjusted pipeline value, led by lerodalcibep in Hypercholesterolemia (Phase 3), across $125B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| lerodalcibep Small moleculeCompletedNCT05234775 | Hypercholesterolemia | Phase 3 | COMPLETED | 188 | Jul 11, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every MEDP program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Troendle August J.Director, Officer (President & CEO), 10% Owner | Sell | -21,966 338,225 held | $625.47 | 09/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MEDP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| IRON TRIANGLE PARTNERS LP | 3.3 % (-62.9 %) | 29.90 M | 90.00 K | -53.33% ( -102.84 K) |
MEDP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-03-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MEDP ranks across every disease it competes in
Competitive Position is a premium feature
See how MEDP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMEDP News
-MEDP
Sep 22, 2026Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026
Medpace Holdings, Inc. has announced the date for its third quarter 2026 financial results, which will be reported after market close on October 21, 2026. A conference call is scheduled for the following morning, allowing stakeholders to discuss the results. Registration is recommended for those wishing to participate.
Read more →-MEDP
Jul 22, 2026▲ +14.7%on this news
Medpace Holdings, Inc. Reports Second Quarter 2026 Results
Medpace Holdings, Inc. reported a significant revenue increase of 17.2% for the second quarter of 2026, reaching $707.3 million compared to $603.3 million in the same period last year. This growth was consistent even when adjusted for currency fluctuations. The company continues to show strong financial performance.
Read more →-MEDP
Jun 16, 2026Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
Medpace Holdings, Inc. has announced that it will report its financial results for the second quarter of 2026 on July 22, 2026. This announcement provides stakeholders with a timeline for when to expect the financial performance details of the company. The report will likely include insights into the company's operations and financial health.
Read more →-MEDP
Apr 22, 2026Medpace Holdings, Inc. Reports First Quarter 2026 Results
Medpace Holdings, Inc. has reported its financial results for the first quarter of 2026. The article does not provide specific details about the performance metrics or any significant events related to the results. The information appears to be limited and lacks context.
Read more →-MEDP
Apr 22, 2026Investor Contact Lauren Morris 283-227-6409 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Michael Maley 283-227-6367 m.maley medpace.com Medpace Holdings, Inc. Reports First Quarter 2026 Results Revenue of $70
Medpace Holdings, Inc. reported its financial results for the first quarter of 2026, highlighting substantial revenue growth of 26.5% compared to the previous year, amounting to $706.6 million. The company's net new business awards also increased by 23.7%, resulting in a net book-to-bill ratio of 0.88x. However, despite growing revenue and EBITDA, the net income margin saw a decline, and a key executive's upcoming resignation was announced, potentially affecting future strategy. The company forecasts continued growth for 2026 with revenues projected between $2.755 billion and $2.855 billion.
Read more →-MEDP
Mar 25, 2026Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026
Medpace Holdings, Inc. announced it will report its first quarter 2026 financial results on April 22, 2026. A conference call will follow on April 23, 2026, at 9:00 a.m. ET for discussion of these results. Interested participants must register in advance, and a webcast will also be available.
Read more →-MEDP
Feb 10, 2026▼ -15.9%on this news
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results
Medpace Holdings, Inc. reported strong financial results for Q4 and full year 2025, with revenues increasing by 32% year-over-year in Q4 and 20% for the full year. The company also announced a positive outlook for 2026, projecting revenue growth between 8.9% and 12.8%. However, total direct costs and SG&A expenses have risen, impacting net income margins.
Read more →-MEDP
Feb 9, 2026Investor Contact Lauren Morris 283-227-6409 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Michael Maley 283-227-6367 m.maley medpace.com Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results
Medpace Holdings, Inc. reported strong financial results for the fourth quarter and full year ended December 31, 2025. Revenue increased by 32.0% to $708.5 million, while net new business awards rose by 39.1%, resulting in a net book-to-bill ratio of 1.04. GAAP net income for Q4 2025 was $135.1 million, reflecting an increase from the previous year. For 2026, the company projects revenue growth between 8.9% and 12.8%, indicating continued optimism in its business outlook.
Read more →-MEDP
Jan 5, 2026Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 9, 2026
Medpace Holdings, Inc. announced it will report its fourth quarter and fiscal year 2025 financial results on February 9, 2026. A conference call is scheduled for February 10, 2026, to discuss these results. Interested participants can register in advance and access the call via telephone or webcast.
Read more →-MEDP
Oct 22, 2025Investor Contact Lauren Morris 283-227-6409 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Michael Maley 283-227-6367 m.maley medpace.com Medpace Holdings, Inc. Reports Third Quarter 2025 Results Revenue of $65
Medpace Holdings, Inc. reported third quarter 2025 results showing a revenue of $659.9 million, a 23.7% increase compared to the same quarter last year. Net new business awards reached $789.6 million, reflecting a growth of 47.9%, leading to a net book-to-bill ratio of 1.20x. The company's GAAP net income for the quarter was $111.1 million, translating to $3.86 per diluted share. Overall, Medpace's strong performance highlights its successful expansion and financial stability despite a slight dip in net income margin.
Read more →-MEDP
Sep 23, 2025Medpace Holdings, Inc. to Report Third Quarter 2025 Financial Results on October 22, 2025
Medpace Holdings, Inc. will release its third quarter 2025 financial results on October 22, 2025. A conference call is scheduled for the following morning, where company representatives will discuss the results. Interested participants can register in advance for the call and access a webcast through Medpace's investor website.
Read more →-MEDP
Jul 21, 2025Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Michael Maley 513.579.9911 x12831 m.maley medpace.com Medpace Holdings, Inc. Reports Second Quarter 2025 Results
Medpace Holdings, Inc. reported its financial results for the second quarter of 2025, highlighting a revenue growth of 14.2% year-over-year, totaling $603.3 million. The company achieved net new business awards of $620.5 million, reflecting a 12.6% increase over the prior-year period. Despite this positive performance, Medpace experienced a slight decline in its net income margin from 16.7% to 15.0%. Additionally, the backlog showed a decrease of 1.8% from June 2024 to June 2025. For the full year, the company forecasts revenue growth between 14.7% to 19.5% over 2024.
Read more →-MEDP
Apr 21, 2025Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Michael Maley 513.579.9911 x12831 m.maley medpace.com Medpace Holdings, Inc. Reports First Quarter 2025 Results
Medpace Holdings, Inc. reported its financial results for the first quarter of 2025, highlighting a 9.3% increase in revenue to $558.6 million compared to the previous year. However, net new business awards saw a decline of 18.8%, leading to a book-to-bill ratio of 0.90x. Despite these challenges, the company achieved a net income of $114.6 million, reflecting an increase from prior year figures. Looking ahead, Medpace projects its 2025 revenue to grow slightly, estimating between $2.140 billion and $2.240 billion.
Read more →-MEDP
Feb 10, 2025Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Michael Maley 513.579.9911 x12831 m.maley medpace.com Medpace Holdings, Inc. Reports Fourth Quarter and Full Yea
Medpace Holdings, Inc. reported its financial results for the fourth quarter and full year of 2024, showing a 7.7% increase in revenue compared to the same period in 2023. The company's GAAP net income rose to $117 million for Q4 2024, compared to $78.3 million in the previous year. However, net new business awards decreased by 13.8%, impacting the net book-to-bill ratio, which stood at 0.99x. Looking ahead, Medpace projects revenue growth of up to 4.8% for 2025.
Read more →-MEDP
Oct 21, 2024Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Michael Maley 513.579.9911 x12831 m.maley medpace.com Medpace Holdings, Inc. Reports Third Quarter 2024 Results
Medpace Holdings, Inc. reported its third quarter 2024 financial results, highlighting an 8.3% increase in revenue to $533.3 million compared to the prior year. The company experienced significant growth in GAAP net income, which rose to $96.4 million, alongside a 31.7% increase in EBITDA, reaching $118.8 million. However, net new business awards saw a decline of 12.7%, resulting in a stable net book-to-bill ratio of 1.00x. Medpace forecasts a revenue range of $2.090 billion to $2.130 billion for the full year 2024, indicating continued growth expectations despite the recent decline in new business awards.
Read more →-MEDP
Jul 22, 2024Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Julie Hopkins 513.579.9911 x12627 j.hopkins medpace.com Medpace Holdings, Inc. Reports Second Quarter 2024 Resul
Medpace Holdings, Inc. reported its financial results for the second quarter of 2024, showcasing a 14.6% increase in revenue to $528.1 million compared to the same period last year. The company achieved significant net income of $88.4 million, resulting in a notable increase in net income margin. However, net new business awards saw a slight decline of 4.1%, indicating a potential challenge in maintaining growth momentum. Despite the increase in operating costs, the company generated strong cash flow, reinforcing its financial stability.
Read more →-MEDP
Apr 22, 2024Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Julie Hopkins 513.579.9911 x12627 j.hopkins medpace.com Medpace Holdings, Inc. Reports First Quarter 2024 Result
Medpace Holdings, Inc. reported strong financial results for the first quarter of 2024, with revenues of $511 million, up 17.7% from the previous year. Net new business awards also rose by 10.8%, resulting in a book-to-bill ratio of 1.20x. The company reported GAAP net income of $102.6 million, up from $72.9 million the year prior, while EBITDA increased by 24.6% to $115.7 million. Medpace forecasts a revenue growth of 14% to 16.7% for the full year 2024, projecting total revenues to range between $2.15 billion and $2.2 billion.
Read more →-MEDP
Feb 12, 2024Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Julie Hopkins 513.579.9911 x12627 j.hopkins medpace.com Medpace Holdings, Inc. Reports Fourth Quarter and Full Y
Medpace Holdings, Inc. reported strong financial results for the fourth quarter and full year of 2023, with revenues reaching $498.4 million for Q4, a 26.5% increase from the previous year. The company also achieved net new business awards of $614.7 million in Q4 2023, which translates to a net book-to-bill ratio of 1.23x. For the full year, revenue grew by 29.2% to $1.885 billion, and a positive forecast was given for 2024 with expected revenues between $2.150 and $2.200 billion. However, there was a noted decline in the net income margin from 17.4% to 15.7%, and total direct costs increased significantly year-over-year.
Read more →-MEDP
Oct 23, 2023Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Julie Hopkins 513.579.9911 x12627 j.hopkins medpace.com Medpace Holdings, Inc. Reports Third Quarter 2023 Result
Medpace Holdings, Inc. has reported strong third quarter results for 2023, showing a revenue increase of 28.3% year-over-year to $492.5 million. The company's net new business awards also rose by 29.9%, contributing to a robust book-to-bill ratio of 1.24x. Despite modest growth in EBITDA, Medpace achieved a net income margin of 14.3%. The company is optimistic with its financial guidance, forecasting full-year revenue between $1.870 billion and $1.890 billion for 2023.
Read more →-MEDP
Jul 24, 2023Investor Contact Lauren Morris 513.579.9911 x11994 l.morris medpace.com FOR IMMEDIATE RELEASE Media Contact Julie Hopkins 513.579.9911 x12627 j.hopkins medpace.com Medpace Holdings, Inc. Reports Second Quarter 2023 Resul
Medpace Holdings, Inc. reported strong financial results for the second quarter of 2023, with revenue increasing by 31.2% year-over-year to $460.9 million. The company also saw an increase in net new business awards, totaling $574.8 million, resulting in a net book-to-bill ratio of 1.25x. Despite positive growth in revenue and net income, the net income margin experienced a slight decline. Medpace forecasts continued growth for 2023, with expected revenue between $1.840 billion and $1.880 billion.
Read more →About Medpace Holdings, Inc. Common Stock
Headquarters5375 MEDPACE WAY, CINCINNATI, OH, 45227
BIOPHARMAWATCH ELITE PLUS
Trade the next MEDP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime